Core Insights - Assembly Biosciences, Inc. is developing ABI-5366, a long-acting helicase-primase inhibitor for recurrent genital herpes, with interim proof-of-concept data expected in fall 2025 [1][5] - The company presented data on ABI-5366 at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases, highlighting its potential as a once-weekly or once-monthly oral treatment option [1][2][8] Clinical Data - ABI-5366 was well tolerated in a Phase 1a study, with no serious adverse events reported at doses up to 350 mg, and a half-life of approximately 20 days supports infrequent dosing [3][4] - Preclinical studies demonstrated broad activity against HSV-1 and HSV-2, reinforcing the potential for weekly or monthly oral dosing [4] Genital Herpes Prevalence and Treatment Patterns - A retrospective analysis estimated 262,457 total genital herpes cases and 148,067 recurrent cases in 2023 among healthcare-engaged individuals in the U.S., with a projected 1.35 million individuals experiencing recurrent genital herpes nationwide [6][7] - Among recurrent cases, 97% received pharmacologic treatment, with 57% on suppressive therapy, indicating a significant opportunity for improved treatment strategies [7] Company Overview - Assembly Biosciences focuses on innovative therapeutics for serious viral diseases, including herpesvirus and hepatitis infections, aiming to enhance patient outcomes [12]
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress